Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 10/20 | 0.33 |
| ▸ | CDK2 | P24941 | 10/20 | 0.33 |
| ▸ | CCND1 | P24385 | 7/20 | 0.33 |
| ▸ | CDK6 | Q00534 | 7/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31722161 | 0.98 | GNAI3 (0.32) | CCNE1CDK2CCND1CDK6TP53 | |
| SCHEMBL24890440 | 0.88 | PDK1 (0.33) | TP53 | |
| SCHEMBL12765361 | 0.88 | PDK1 (0.33) | TP53 | |
| SCHEMBL14971519 | 0.80 | MEN1 (0.44) | — | |
| SCHEMBL12765367 | 0.78 | MAPK1 (0.40) | CCNE1CDK2CCND1CDK6TP53 | |
| SCHEMBL12765346 | 0.78 | — | — | |
| SCHEMBL2430641 | 0.78 | SMYD3 (0.33) | TP53SMYD3 | |
| SCHEMBL16977907 | 0.78 | NCF1 (0.47) | CCNE1CDK2CCND1CDK6TP53 | |
| SCHEMBL26343648 | 0.78 | TP53 (0.37) | TP53SMYD3 | |
| SCHEMBL2428229 | 0.78 | GNAI3 (0.34) | TP53SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114394966-B | Pyridopyrimidinone CDK2/4/6 inhibitors | 辉瑞公司 | 2024-10-11 | — | — | CN | disclosed |
| US-20230303564-A1 | PYRIMIDINE RING COMPOUND | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303564-A1 | PYRIMIDINE RING COMPOUND | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. (CN) | 2023-09-28 | — | — | US | disclosed |
| CN-116601155-A | Heteroaryl quinazoline compounds as protein kinase inhibitors | 成都赛璟生物医药科技有限公司 | 2023-08-15 | — | — | CN | disclosed |
| US-20220324872-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2022-10-13 | — | — | US | disclosed |
| US-11396512-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2022-07-26 | — | — | US | disclosed |
| US-11396512-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2022-07-26 | — | — | US | disclosed |
| WO-2022111634-A1 | HETEROARYLQUINAZOLINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | 成都赛璟生物医药科技有限公司 | 2022-06-02 | — | — | WO | disclosed |
| EP-3497103-B1 | PYRIDOPYRIMDINONE CDK2/4/6 INHIBITORS | PFIZER (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20200392142-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2020-12-17 | — | — | US | disclosed |
| US-10233188-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2019-03-19 | — | — | US | disclosed |
| WO-2018033815-A1 | PYRIDOPYRIMDINONE CDK2/4/6 INHIBITORS | PFIZER INC. (US) | 2018-02-22 | — | — | WO | disclosed |
| US-20180044344-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2018-02-15 | — | — | US | disclosed |
| US-20180044344-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2018-02-15 | — | — | US | disclosed |
| CN-102171204-B | 8-substituted isoquinoline derivative and application thereof | ASAHI KASEI PHARMA CORP | 2014-08-20 | — | — | CN | disclosed |
| EP-2366699-B1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2013-08-07 | — | — | EP | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| EP-2366699-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2011-09-21 | — | — | EP | disclosed |
| CN-102171204-A | 8-substituted isoquinoline derivative and application thereof | ASAHI KASEI PHARMA CORP | 2011-08-31 | — | — | CN | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324872-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | CCNE1 29/4885CDK2 1/4885CCND1 40/4885 |
| US-20230303564-A1 | PYRIMIDINE RING COMPOUND | DPYD, TYMS, TYMP | CCNE1 1815/4885CDK2 165/4885CCND1 1592/4885 |
| US-20200392142-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | CCNE1 28/4885CDK2 1/4885CCND1 39/4885 |
| US-11396512-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | CCNE1 29/4885CDK2 1/4885CCND1 40/4885 |
| US-20180044344-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | CCNE1 29/4885CDK2 1/4885CCND1 40/4885 |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | RELA, NFKBIA, NFKB2 | CCNE1 580/4885CDK2 193/4885CCND1 623/4885 |
| US-10233188-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | CCNE1 29/4885CDK2 1/4885CCND1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.